Bone matters in lung cancer
Brodowicz, T., O'Byrne, Kenneth J., & Manegold, C. (2012) Bone matters in lung cancer. Annals of Oncology, 23(9), pp. 2215-2222.
Background: Bone metastases are a significant and undertreated clinical problem in patients with advanced lung cancer.
Design: We reviewed the incidence of bone metastases and skeletal-related events (SREs) in patients with lung cancer and examined the burden on patients' lives and on health care systems. Available therapies to improve survival and lessen the impact of SREs on quality of life (QoL) were also investigated.
Results: Bone metastases are common in lung cancer; however, owing to short survival times, data on the incidences of SREs are limited. As with other cancers, the costs associated with treating SREs in lung cancer are substantial. Bisphosphonates reduce the frequency of SREs and improve measures of pain and QoL in patients with lung cancer; however, nephrotoxicity is a common complication of therapy. Denosumab, a recently approved bone-targeted therapy, is superior to zoledronic acid in increasing the time to first on-study SRE in patients with solid tumours, including lung cancer. Additional roles of bone-targeted therapies beyond the prevention of SREs are under investigation.
Conclusions: With increasing awareness of the consequences of SREs, bone-targeted therapies may play a greater role in the management of patients with lung cancer, with the aim of delaying disease progression and preserving QoL. © The Author 2012. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
Impact and interest:
Citation counts are sourced monthly from and citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
Full-text downloads displays the total number of times this work’s files (e.g., a PDF) have been downloaded from QUT ePrints as well as the number of downloads in the previous 365 days. The count includes downloads for all files if a work has more than one.
|Item Type:||Journal Article|
|Additional Information:||Articles free to read on journal website after 12 months|
|Keywords:||Bone metastases, Lung neoplasms, Neoplasm metastases, Quality of life, Skeletal-related events, bevacizumab, bisphosphonic acid derivative, carboplatin, cisplatin, denosumab, gefitinib, mitomycin C, placebo, vinblastine, zoledronic acid, bone metastasis, bone pain, bone scintiscanning, cancer survival, drug efficacy, drug megadose, drug response, drug targeting, gastrointestinal toxicity, health care cost, human, jaw osteonecrosis, lung cancer, lung non small cell cancer, nephrotoxicity, nonhuman, pain assessment, priority journal, review, solid tumor, spinal cord metastasis, survival time, treatment outcome, Animals, Bone Neoplasms, Carcinoma, Non-Small-Cell Lung, Clinical Trials as Topic, Health Care Costs, Humans, Molecular Targeted Therapy, Pain Management|
|Divisions:||Current > Schools > School of Biomedical Sciences
Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
|Copyright Owner:||Copyright 2012 Oxford University Press|
|Deposited On:||27 Nov 2013 06:22|
|Last Modified:||10 Apr 2017 05:26|
Repository Staff Only: item control page